TargaZyme

The Next Frontier of Cancer Medicine

Print
Claim My Business View on StartEngine
Security Type
Common Stock
Categories
Healthcare/Medical
Min Investment
$596
Location
Carlsbad, CA
Expected Close Date
August 18, 2022
Amount Raised
$34,539
Target Raise
$10K-$1M
No. Investors
45
Security Price
$6.62
Valuation
$100,000,000
Number of Employees
2
Cash
$111,900
Revenue
$0
Short Term Debt
$7,524,097
Cost of Goods
$0
Long Term Debt
$441,014
Net Income
$-2,416,916

Company Description

TargaZyme is pioneering the next frontier of cancer medicine with the development of therapeutics that harnesses the power of a patient’s own immune system without the toxic chemotherapies, radiation, radical surgery or other toxic cancer drugs that make up today’s standard of care. TargaZyme is currently pre-revenue and in the R&D stage with our two breakthrough approaches: TZ101, a Phase-3 ready product, and TZ102, which is currently being prepared for clinical or human-patient trials.

Perks

StartEngine OWNERS Exclusive Click here to learn more

$331+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Friends and Family Early Birds
Invest within the first week and receive 10% Bonus Shares




2
days

5
hours

33
mins

5
secs

$5,000+ Investment
$5,000+ Invest $5,000+ and receive 5% Bonus Shares

$10,000+ Investment
$10,000+ Invest $10,000+ and receive 10% Bonus Shares

Key Deal Facts

A single dose of our novel patented medicine TZ101 was shown to improve survival of terminally ill cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant by preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure in a Phase 2 clinical (human) trial at M D Anderson Center in Texas in 2015..
TargaZyme has been awarded over 38 worldwide patents, with over 40 patent-pending applications, and multiple orphan drug awards.
We have received $50m+ in funding to date, of which, $40m+ originated from highly prestigious medical awards. The team has worked with leading medical centers including MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, and Cleveland Clinic.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments